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A B S T R A C T
Background
Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a
wide range of diagnoses including cancer. The current literature indicates that pain is not well managed, however the evidence base to
guide clinicians is limited. There is a clear need for evidence from a systematic review to inform prescribing.
Objectives
To evaluate the evidence on the effectiveness of different pharmacological interventions used for pain in CYP with LLCs.
Search methods
The following electronic databases were searched up toDecember 2014: CENTRAL (in the Cochrane Library), MEDLINE, EMBASE,
PsycINFO and CINAHL. In addition, we searched conference proceedings and reference lists of included studies. For completeness,
we also contacted experts in the field. No language restrictions were applied.
Selection criteria
Randomised controlled trials (RCTs), quasi-randomised studies and other studies that included a clearly defined comparator group
were included. The studies investigated pharmacological treatments for pain associated with LLCs in CYP. The treatment included
those specifically developed to treat pain and those that acted as an adjuvant, where the treatment was not primarily developed to treat
pain but has pain relieving properties. The LLC was identified by its inclusion in the Richard Hain Directory of LLCs.
Data collection and analysis
Citations were screened by five review authors. Data were extracted by one review author and checked by a second. Two review authors
assessed the risk of bias of included studies. A sufficient number of studies using homogeneous outcomes was not identified so a meta-
analysis was not possible.
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Main results
We identified 24,704 citations from our database search. Nine trials with 379 participants fulfilled our inclusion criteria. Participants
had cerebral palsy (CP) in five of the studies and osteogenesis imperfecta (OI) in the other four. Participants across the trials ranged in
age from 2 to 19 years. All studies, apart from one cross-over trial, were parallel designed RCTs. Three of the trials on CP evaluated
intrathecal baclofen (ITB) and two botulinum toxin A (BoNT-A). All of the OI trials evaluated the use of bisphosphonates (two
alendronate and one pamidronate). No trials were identified that evaluated a commonly used analgesic in this patient group. Pain was
a secondary outcome in five of the eight identified studies. Overall the quality of the trials was mixed. Only one study involved over
100 participants.
For the two ITB studies for pain in CP, in the same study population but assessed at different time points in their disease, both found
an effect on pain favouring the intervention compared to the control group (standard care or placebo) (mean difference (MD) 4.20,
95% confidence interval (CI) 2.15 to 6.25; MD 26.60, 95% CI 2.61 to 50.59, respectively). In these studies most of the adverse events
related to the procedure or device for administration rather than the drug, such as swelling at the pump site. In one trial there were also
eight serious adverse effects; these included difficulty swallowing and an epileptic seizure. The trial did not state if these occurred in the
intervention group. At follow-up in both BoNT-A trials there was no evidence of a difference in pain between the trial arms among CP
participants. The adverse events in the BoNT-A trials mostly involved those who received the intervention drug and involved seizures.
Gastrointestinal problems were the most frequent adverse event in those who received alendronate. The trial investigating pamidronate
found no evidence of a difference in pain compared to the control group. No adverse events were reported in this trial.
Authors’ conclusions
Published, controlled evidence on the pharmacological interventions for pain in CYP with LLCs is limited. The evidence that is
currently available evaluated pain largely as a secondary outcome and the drugs used were all adjuvants and not always commonly
used in general paediatric palliative care for pain. Based on current data this systematic review is unable to determine the effects of
pharmacological interventions for pain for CYP with LLCs. Future trials with larger populations should examine the effects of the
drugs commonly used as analgesics; with the rising prevalence of many LLCs this becomes more necessary.
P L A I N L A N G U A G E S U M M A R Y
Drug treatments for pain in children and young people with life-limiting conditions
Pain is commonly experienced in children and young people with diseases that are not curable and which may shorten their lives. These
may be cancers or other diseases. Sometimes the pain is under-treated, particularly for those nearing the end of their lives. There are
many different types of drugs that have been developed to treat pain. There are also drugs that were not developed primarily to treat
pain but which have an action that may provide pain relief. However, clinical guidelines to support doctors in their choice of treatment
for pain are limited. This is because there are few trials specifically in children and young people that have tested the benefits and safety
of such drugs.
In this review we sought to find out precisely what the evidence is on drug treatments for pain in children and young people with
diseases that are not curable and that may shorten their lives.
We searched five large databases of published research projects. We found nine relevant randomised controlled trials. Five were for
children and young people with cerebral palsy and four for those with a degenerative bone disease called osteogenesis imperfecta.
Overall, these trials did not find clear evidence of a benefit of the drugs tested in the treatment of pain. This was apart from the two on
cerebral palsy where pain relief occurred with the use of baclofen delivered via a catheter into the spinal cord. However the procedure to
deliver this medication resulted in most side effect reported in these trials; this was swelling at the site of the catheter, and in one study
it reported that this occurred in around half of the children (8/17). Five children also leaked spinal fluid from the catheter resulting in
headache and nausea and, for two children, a prolonged hospital stay.
The trials were limited by the quality of their methods and most did not set out to measure the benefit of the drug in reducing pain as
a main focus. In conclusion, the evidence on pain treatment in children and young people with life-limiting health conditions is very
limited, and only evaluated in participants with certain diseases and not for drug treatments primarily used to treat pain. The trials
that were identified evaluated the drugs in small samples of children. There remains a need for more research to help guide doctors in
their decisions on how to treat pain in these children and young people.
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B A C K G R O U N D
Description of the condition
Pain is one of the most common symptoms in children and young
people (CYP) with life-limiting conditions (LLCs) (Beretta 2010;
Feudtner 2011; Wolfe 2000). In this review, LLC refers to ‘any
condition for which there is no reasonable hope of cure and from
which the child or young adult will die prematurely’. LLCs are
also defined as ‘those for which curative treatment may be feasible
but can fail’ (ACT 2009). LLCs are seen to be rising in the UK
(Fraser 2012), with 32 per 10,000 CYP having an LLC. Sources
of pain in this population include ongoing tissue damage due
to pathological processes, recurrent injury, therapy and invasive
diagnostic or therapeutic procedures.
Increasing evidence suggests that pain is not well managed in such
CYP, especially towards the end of life. In one large cross-sectional
study of CYP with cancer deemed ‘palliative’, Goldman 2006
found that 91.5% of the 164 CYP in the study experienced pain
in the month before death. In another study, 87% of 47 CYP with
cancer experienced pain during the ‘end stage’ (Beretta 2010); and
in an earlier study 53% of 30 ‘dying’ CYP experienced pain in the
last week of their lives (Drake 2003).
Types of pain
Pain can be characterised in several ways, of which none is deemed
a gold standard. Pain can, for example, be characterised by mech-
anism or pathophysiology, intensity, temporality or by location.
1. Pain mechanisms
Two basic pain mechanisms are known, nociceptive and neuro-
pathic. Nociceptive pain occurs as the result of tissue damage or
inflammation due to physical, chemical or thermal injury (for ex-
ample traumatic or ischaemic pain, arthritis, muscle spasm, mu-
cositis, gastritis, or other visceral inflammatory processes). Neu-
ropathic pain occurs when a lesion of the central or peripheral
nervous system causes nociceptive dysfunction (IASP 2012) (for
example from direct tumour invasion or neural toxicity from che-
motherapy or infection). Nociceptive and neuropathic pain can
occur separately or together, in the same individual. The impor-
tance of distinguishing between these twomechanisms is that anal-
gesics are developed for action on specific mechanisms, and so an
outcome can vary depending on the type of pain.
2. Intensity
Pain intensity is usually measured on a scale of 0 to 10, or 0 to 100,
using a linear visual analogue scale (VAS). It may also be measured
by another pain intensity measurement tool such as the Wong-
Baker Faces Scale (Wong 1988). Intensity can be described us-
ing a four-point categorical pain intensity scale with correspond-
ing wording, none, mild, moderate, severe. Intensity may also be
characterised in theWorldHealthOrganization (WHO) two-step
pain management algorithm, mild (VAS 4 to 6), moderate (VAS
7 to 8) or severe (VAS 9 to 10). This algorithm recommends phar-
macological interventions of increasing potency to be used for
mild and moderate to severe pain (WHO 2012). The 2012 ver-
sion of the WHO document differs from the original three-step
ladder, which included a middle step of using a ‘weaker’ opioid for
moderate pain before a ‘stronger’ opioid in the third step (WHO
1996). Pain intensity measurement is potentially more complex in
CYP who are too young, preverbal or non-verbal, and are unable
to describe or quantify their pain. The literature on this subject
is enormous, and a large number of pain measurement tools suit-
able for CYP of different ages in a variety of settings have been
devised (Stinson 2006; Von Baeyer 2009). However, no definitive
tools adequately measure persistent pain in CYP with palliative
care needs. It is important to recognise that in clinical studies, the
accuracy and reliability of such tools depend on their validity for
use in the situation described (see also Secondary outcomes).
3. Temporality
Pain can be described by its temporality although, as is emphasised
in the WHO guidelines, temporality does not define treatment
strategies. Such pain can be described as:
• acute pain (< 30 days),
• chronic pain (> 3 months, with behaviours in response to
pain that does not remit (Hain 2011),
• persistent pain (covers long-term pain related to medical
illness),
• episodic or recurrent pain (occurs intermittently over a long
period of time and the child can be pain free in between each
painful episode),
• breakthrough pain (temporary increase in the severity of
pain over and above the pre-existing baseline pain level, and can
be predictable or unpredictable with or without an identifiable
cause),
• incident pain (from an identifiable cause),
• end of dose pain (occurs before a scheduled dose of an
around-the-clock analgesic) (WHO 2012).
4. Location
Pain is sometimes characterised by its location in the body, such
as bone pain, headache, abdominal pain or musculoskeletal pain.
Description of the intervention
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For this review, we have focused on pharmacological interventions
for the relief of pain causally related to the LLC (disease-related
pain). Pain due to diagnostic and therapeutic procedures and post-
operative pain have been excluded from this review.
We have assessed the evidence on the effectiveness of pharmaco-
logical interventions using a framework adapted from the WHO
guidelines for pain management in CYP with medical conditions
(WHO 2012). These include the following.
1. Non-opioid analgesics such as paracetamol and non-steroidal
anti-inflammatory drugs (NSAIDs).
2. Opioids such as morphine, methadone, hydromorphone,
buprenorphine, codeine, fentanyl and oxycodone.
3. Local anaesthetics such as lidocaine, bupivacaine and levo-bupi-
vacaine.
4. Adjuvant analgesics. This group includes all drugs given for pain
but their primary indication is not analgesia. For example, most
drugs commonly used for neuropathic pain can act or be specifi-
cally used as an adjunct analgesic, such as tricyclic antidepressants
(TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), and anticonvulsants
such as gabapentin and carbamazepine. Muscle relaxants and an-
tispasmodics such as baclofen and hyoscine, steroids, the adrener-
gic analgesic clonidine and the N-methyl-D-aspartate (NMDA)
antagonists ketamine and dexmedetomidine are included in this
category. Another is botulinum toxin A (BoNT-A), which is pri-
marily used in CYP with cerebral palsy (CP) as an adjunct to
other therapeutic techniques (such as physiotherapy). It is used as
a means of reducing muscle tone and spasticity.
How the intervention might work
Pharmacological interventions used to treat pain in CYP with
LLCs are numerous and varied; theywork indifferent and complex
ways, with somemechanisms of action still poorly understood.We
have briefly considered the mechanisms of action according to the
above groupings, giving examples from each group. We recognise
that these interventions may be used for pain from a variety of
causes, occurring in a variety of temporalities and in a range of
clinical conditions as defined by the International Classification
of Diseases and Related Health Problems, 10th Revision (ICD-
10) codes.
1. Non-opioids
Non-opioid analgesics traditionally include paracetamol and the
NSAIDs (for example ibuprofen, diclofenac, ketorolac). Some of
these analgesics, such as ketorolac and diclofenac, are still of un-
certain potency. Paracetamol is an analgesic and antipyretic and is
probably the most popular simple analgesic used in CYP for pain
of mild to moderate intensity (Anderson 2008). Paracetamol has
numerous putative mechanisms of analgesia, such as inhibiting
prostaglandin synthesis within the CNS (cyclo-oxygenase (COX)-
3, COX-2b), blocking impulse generation within the bradykinin-
sensitive chemoreceptors responsible for the generation of noci-
ceptive impulses, and antagonising NMDA (Jacqz-Aigrain 2006).
The recommended oral dosage starts at 20 mg/kg as a single dose,
then 10 to 15 mg/kg every 8 to 12 hours for neonates up to 500
mg; 1 g every 4 to 6 hours for 16- to 18-year olds (BNF 2012).
NSAIDs are a diverse group of drugs that share similar antipyretic,
analgesic and anti-inflammatory effects but may show different
response characteristics (Jacqz-Aigrain 2006). Ibuprofen, for ex-
ample, is a propionic acid derivative and a non-selective COX
inhibitor, and its recommended dosage ranges from 5 mg/kg for
infants aged 1 to 3 months up to 300 to 400 mg for CYP 12 to
18 years old, 3 to 4 times daily by mouth (BNF 2012).
2. Opioids
Numerous opioids are used to relieve pain in CYP with LLCs, in-
cluding (but not limited to) morphine, codeine, buprenorphine,
fentanyl, methadone and oxycodone. Opioids bind to specific re-
ceptors found principally in the central nervous system and the
gastrointestinal tract. Morphine is widely regarded as the first-
line major opioid in CYP with LLCs who are experiencing severe
pain. Morphine acts directly on opioid receptors; and a principal
metabolite morphine-6-glucuronide (M6G) also has analgesic ac-
tivity. Opioids can cause constipation and itch, as well as serious
adverse effects such as extreme somnolence anddepressionof respi-
ration, particularly when used in excess in opioid-naive individuals
and young infants. Age-related changes in the pharmacokinetics
of opioids are still not well understood. However, it is known that
most age-related changes are more apparent in the first year of life
(as the result of pharmacokinetic differences, particularly reduced
renal clearance in the first few months of life) and from then on
the ability of CYP to metabolise opioids seems similar to that of
adults (Ballentine 2012). Total body morphine clearance is 80%
of adult values by six months of age (Bouwmeester 2004). How-
ever, it has been shown that M6G may have faster renal clearance
in CYP, and therefore they may actually need higher doses given
at shorter intervals than in adults (Mashayekhi 2009). Data on
the use of opioids in CYP with LLCs are lacking (Zernikow 2009)
and ongoing debate requires further study to provide conclusive
evidence.
3. Local anaesthetics
Local anaesthetics are ion channel (Na+) blocking drugs that can
treat andprevent all types of pain by blockingnociceptive pathways
and suppressing nociceptor excitability. They are normally given
by injection close to nerves peripherally or centrally (intrathecal
or epidural) but topical preparations, including a low-dose trans-
dermal patch formulation that is effective for some types of neu-
ropathic pain, are also available. Local anaesthetics in clinical use
4Pharmacological interventions for pain in children and adolescents with life-limiting conditions (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
include the amides lidocaine, bupivacaine and levo-bupivacaine,
and the esters benzocaine, tetracaine and chloroprocaine.
4. Adjuvants
Adjuvants of interest in this review are drugs with a primary in-
dication that is not for pain but that nevertheless have analgesic
properties. Examples of adjuvants for neuropathic pain include
some anticonvulsants, antidepressants, steroids and the NMDA
antagonist ketamine. Skeletal muscle relaxants such as baclofen
and antispasmodics such as hyoscine are sometimes given for pain
relief. Another example is botulinum toxin A (BoNT-A), which
is used in cerebral palsy as a means of reducing muscle tone and
spasticity. Bisphosponates are used to slow bone loss and, in turn,
have an analgesic effect. Adjuvants make up a varied group and
work in many different ways. In this review we have considered
only adjuvants that are explicitly administered for pain relief.
Routes of administration
In CYP the preferred route, where possible, is oral because it is the
simplest, most effective and least painful (WHO 2012). However,
other routes are frequently necessary because of varying clinical
needs. Examples include buccal, rectal, transdermal, intramuscu-
lar, subcutaneous, intravenous, epidural and intrathecal routes.
Why it is important to do this review
The evidence base that is currently available to guide clinical prac-
tice in this area of pain management in CYP with LLCs is limited
and, whilst some clinical reviews have been published, no system-
atic review of the international literature has been performed to
date. It is recognised, as evidenced in a recent survey conducted by
the Association for Paediatric Palliative Medicine (APPM), that
clinicians have an urgent need for systematic review evidence to
support their prescribing (Brook 2012).
O B J E C T I V E S
To evaluate the evidence on the effectiveness of different pharma-
cological interventions used for pain in CYP with LLCs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We have included randomised controlled trials (RCTs) (including
cluster RCTs and cross-over trials), quasi-randomised studies, n of
1 studies, studies that are not randomised but include a clearly de-
fined comparator group, and time series analyses that have inves-
tigated pharmacological treatments for pain associated with LLCs
in CYP.
Types of participants
Trials with participants who were CYP aged 0 to 18 years of either
sex and with pain related to their LLCs were included. We deter-
mined whether a condition is life-limiting by using the Richard
Hain Directory (Hain 2013) of ICD-10 diagnoses that have been
judged by professionals working in palliative care of CYP to be
life-limiting, and that were recently used in a paper plotting the
national prevalence of LLCs in this population (Fraser 2012). The
directory is neither determinative nor definitive but provides a list
of conditions that can possibly limit life in CYP during their child-
hood or as a young person. As some conditions can present with
a range of severity (such as cerebral palsy) the authors recognise
that this will result in inclusion of some CYP who may not meet
the ACT 2009 definition of life-limiting condition. In addition,
following discussion by members of this review group, one review
author (EB) contacted the lead author of the directory to enquire
about the classification of osteogenesis imperfecta (OI) as a LLC,
as this diagnosis was not listed in the original directory. OI has
since been added to the directory. The conditions listed in the di-
rectory can be broken down into the following groups: infections;
leukaemia; other malignant neoplasms; other neoplasms; other
diseases of blood and blood-forming organs; cystic fibrosis; other
endocrine, nutritional and metabolic disorders; epilepsy; cerebral
palsy and other paralytic syndromes; other disorders of the nervous
system; diseases of the circulatory system; diseases of the respira-
tory system; diseases of themusculoskeletal system and connective
tissue; diseases of the genitourinary system; conditions originating
in the perinatal period; congenital anomalies and other causes; and
non-malignant haematological disorders (Cochrane 2007).
Types of interventions
Interventions included any pharmacological intervention given at
any dose for any time period, on its own or in combination and
with a control or comparator group (see below). The treatment
included those specifically developed to treat pain and those that
acted as an adjuvant where the treatment was not primarily de-
veloped to treat pain but which has pain relieving properties. We
did not include studies on non-pharmacological interventions or
where the treatment for pain was as a result of an investigation or
treatment.
Control or comparator groups included any other pharmacolog-
ical interventions; psychological interventions such as relaxation,
hypnosis and cognitive behavioural therapy; placebo; or alterna-
tive dosing regimens or routes of administration.
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The intervention could be undertaken in any setting, including
home, hospital, hospice and residential school.
Types of outcome measures
For all outcome measures, we have reported on the mechanisms
of reporting pain in this population, which commonly features
preverbal and non-verbal children, and have taken into consider-
ation in our own results the types of outcome measures used (for
example observational, proxy, self-report).
Primary outcomes
The primary outcomes were pain control and adverse events. Pain
control is measured by changes in pain intensity scales; other indi-
cators such as changes in physiological parameters are used (base-
line or final value scores at end of follow-up) and include both
continuous and dichotomous pain outcomes. We have reported
what each paper suggests as an adequate reduction of pain or pe-
riod of maintenance of pain reduction. We planned, as advised
in the ’Authoring or Assessing a Cochrane Protocol, Review, or
Review Update for the PaPaS Review Group’ guidance, to only
include studies that used moderate or greater pain as the baseline
in any meta-analysis (Cochrane 2011); however, this was not ap-
plicable as not enough homogeneous data were available to com-
bine in a meta-analysis. To facilitate the review process, all forms
of pain measurement in CYP, both validated and non-validated,
were considered during the review process. We reported data on
all adverse events identified.
Secondary outcomes
As the effectiveness of analgesia is also measured in terms of
changes in physical and psychological functioning and well-being
(McGrath 2008), we have included assessments using validated in-
struments, psychological or social measures such as mental health
status and functioning scales, quality of life, well-being and qual-
ity of care scales for CYP, such as the Pediatric Quality of Life In-
ventoryTM (PedsQL) (Varni 1999) and European Quality of Life
5-Dimensions (EQ-5D) (Ravens-Sieberer 2010) for their family.
Health service use, including length of stay and number of hospi-
tal admissions, were considered for review. At review stage it was
found that trials may include multiple outcomes, in one case the
trials reported results for over 20 measures. For ease of readability
and interpretation for our review we report ’other outcomes’ to
encompass the many outcomes reported by the studies, we only
present those that were of primary interest in the trials.
Search methods for identification of studies
We used a combination of indexed and free-text terms to reflect
the concepts of ‘pharmacological intervention’, ‘CYP’ and ’pain’.
The LLC element was identified during screening of papers. We
modified the search terms according to the constraints of each
database.
Electronic searches
The following electronic databases were searched.
• CENTRAL (2014, Issue 11 of 12) (in The Cochrane
Library).
• MEDLINE (1946 to week 3 November 2014) (via
OvidSP).
• EMBASE (1974 to 16 December 2014) (via OvidSP).
• PsycINFO (1806 to week 2 December 2014) (via OvidSP).
• CINAHL (1980 to December 2014) (via EBSCOhost).
No language restrictions were applied. Please see Appendix 1 for
the search strategies used.
Searching other resources
We undertook the following additional search strategies.
• Conversations with colleagues or key authors, or a review of
papers that they recommended.
• Contact with key authors who have published in this field.
• Conference proceedings, where available, for the
International Symposium on Paediatric Pain and the European
Association of Palliative Care.
• Forward and backward citation searches of included studies.
• Handsearching of key journals (Journal of Pain and
Symptom Management and Palliative Medicine).
Data collection and analysis
Selection of studies
Five review authors (EB, JL, BC, LJ and HR) screened abstracts
of all identified studies against the inclusion criteria. A second
review author (EB) screened a sample of the same abstracts to
validate the process (10% of the cohort). We retrieved all possi-
bly relevant articles in full text for assessment against the inclu-
sion criteria. We have links to researchers with many different
languages skills within University College London (UCL) and so
were able to translate any non-English studies; however, none were
applicable for translation. We included a PRISMA study flow di-
agram (Liberati 2009) to document the screening process, as rec-
ommended in Part 2, section 11.2.1 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011a).
Data extraction and management
One review author (EB) extracted the data using a standardised
data extraction form developed by the review authors and a second
review author checked the data extraction (BC or LJ). Where
possible, the following information was obtained for each study.
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• The number of patients eligible, the number of participants
randomly assigned, and reasons why patients were not included
in the trial.
• The number of participants evaluated at follow-up(s) and
what the follow-up time points were.
• Participant demographics including age, sex, diagnosis,
ICD-10 code, and type of healthcare setting (hospital, hospice,
home, residential school).
• Trial design features on masking, whether parallel group or
cross-over, features of randomisation, and sample size calculation.
• Any necessary additional data on trial design and outcomes
to allow completion of the Cochrane Collaboration’s tool for
assessing risk of bias.
• Comparison interventions, including duration and mode.
• Outcome data on pain reduction at all time points,
including how an outcome was measured, and mean or
categorical scores of the main outcome and other outcomes.
• Adverse effects.
• Blinding of researchers and participants to the allocation of
those participants receiving the intervention or the control.
• Dropout rates and reasons why.
• Concurrent use of other drugs including analgesics, and any
drug exclusions.
• Quality of life of CYP and family, and how this was
measured.
• Other behavioural and psycho-social measures, and the
scales used to measure them.
In cases where information is lacking, we attempted to make con-
tact with trial authors or trial sponsors.
Assessment of risk of bias in included studies
We assessed and reported on the risk of bias of included RCTs
using the Cochrane Collaboration’s tool for assessing risk of bias
(Higgins 2011a). This recommends explicit reporting of the fol-
lowing quality elements for RCTs: sequence generation; alloca-
tion concealment; blinding; completeness of outcome data; and
selective outcome reporting. For each quality domain, we assessed
whether the risk of bias was low (if the study matched the criteria),
high (if the study did not match the criteria) or unclear (if under-
reporting was noted). We defined trials as having an overall low
risk of bias if they scored a low risk of bias on four of the five
domains in the risk of bias table. We labelled a trial as having an
unclear risk of bias if the trial provided too few details to allow a
judgement of ’high’ or ’low’ risk of bias. Two review authors (EB
and VV) assessed the risk of bias of the included studies; disagree-
ments were resolved by discussion. Where needed, we contacted
study authors to ask for additional information. We incorporated
the results of the risk of bias assessment into the review through
systematic narrative description and commentary about each item.
This led to an overall assessment of the risk of bias of included
studies and a judgement about the internal validity of the results
of the review.
Measures of treatment effect
The null hypothesis tested is that, for the primary outcomes exam-
ined, the pharmacological interventions have no effect compared
with placebo or other interventions. Where there were appropriate
data, for dichotomous outcomes we calculated the risk ratio (RR)
with 95% confidence interval (CI), and for continuous data we
estimated the mean difference (MD) with 95% CI.
Unit of analysis issues
We planned to seek statistical advice if we identified trials using
a cluster design (in which participants were randomly assigned at
group level).
Dealing with missing data
If doubts had arisen about missing data (participant dropouts,
etc.) we would have sought to contact the study authors to obtain
further information and if we are unable to obtain data we would
have stated that. We planned, if needed, to address the potential
impact of missing data on our findings in the ’Discussion’ section
of the review.
Assessment of heterogeneity
A meta-analysis was not conducted and so evaluation of hetero-
geneity between trials (Higgins 2011b) was not necessary.
Assessment of reporting biases
A sufficient number of studies were not identified and so a meta-
analysis was not possible.
Data synthesis
For this review we first sought to categorise the studies according
to whether they considered nociceptive pain, neuropathic pain, or
both. We then grouped the identified evidence by the LLC ICD-
10 (disease) classification and then by the different pharmacolog-
ical interventions used (that is non-opioids, opioids, local anaes-
thetics, and adjuvants). We planned that if there were sufficient
trials by class of treatment, and they were sufficiently similar in
measurement and population and of sufficient quality, we would
combine their individual data in a meta-analysis.
Subgroup analysis and investigation of heterogeneity
Meta-analysis was not conducted and so no subgroup analysis was
undertaken.
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Sensitivity analysis
We planned to perform sensitivity analyses in order to explore (by
excluding trials) the influence of the following factors.
• Unpublished trials.
• Trials at high risk of bias.
Summary of findings tables
We had planned to use the GRADE system (Schunemann 2008)
to assess the quality of the evidence associated with specific out-
comes (for example pain reduction, quality of life improvement,
adverse effects) and construct a ‘Summary of findings’ table using
the GRADE software. However, because of the small cohort of
heterogenous trials that were found, comprising different condi-
tions, drugs and outcomes, a summary of findings table was not
constructed. It would not have added any meaning for the reader
although the authors note that it is possible to create a summary
of findings table despite the lack of meta-analysis.
R E S U L T S
Description of studies
Results of the search
See Characteristics of included studies; Characteristics of excluded
studies.
We identified 24,704 citations fromour electronic database search.
Thirty-nine potential studies were identified from the citations.
We also handsearched all included studies’ bibliographies, searched
other relevant Cochrane reviews (such as reviews on interventions
for pain in other CYP populations) and contacted authors in the
field to enquire for advice on other relevant trials for our review.
This yielded another eight studies for full-text retrieval. See Figure
1.
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Figure 1. Review screening, selection and assessment steps, and numbers at each stage.
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Included studies
On full-text retrieval, nine trials in 10 papers matched our in-
clusion criteria (Bishop 2013; Bonouvrie 2011; Copeland 2014;
Hoving 2007; Hoving 2009 (published in two papers, see refer-
ence); Letocha 2005; Russo 2007; Seikaly 2005; Ward 2011).The
Hoving 2007 and Hoving 2009 trials used the same population
but they tested different interventions; the 2007 trial was a dose
finding study and the 2009 trial reported the longer-term trial. In
addition, we identified one ongoing trial (Bonouvrie 2013).
The nine completed studies involved 379 participants in total.
Three studies were undertaken in North America (Letocha 2005;
Seikaly 2005; Ward 2011), three in the Netherlands (Bonouvrie
2011; Hoving 2007; Hoving 2009), two in Australia (Copeland
2014; Russo 2007) and one in the UK (Bishop 2013). All were
parallel RCTs apart from one cross-over RCT (Seikaly 2005). Five
trials investigated participants with cerebral palsy (CP) (Bonouvrie
2011; Copeland 2014; Hoving 2007; Hoving 2009; Russo 2007).
CP is a disorder ofmovement or posture, or both, as a result of non-
progressive but permanent damage to the developing brain before,
during or immediately after delivery. Pain in CP is likely to be of
mixed nociceptive and neuropathic origin. In the trials that were
included the participants were being treated for spasticity, which
is a muscle control disorder characterised by tight and stiff muscles
and an inability to control the muscles. Three of the trials on CP
were investigating intrathecal baclofen (Bonouvrie 2011; Hoving
2007; Hoving 2009). Baclofen is a muscle relaxant and acts at the
spinal cord level to inhibit the release of excitatory neurotransmit-
ters. Intrathecal baclofen is administered directly into the spinal
fluid and, because oral baclofen is poorly transferred through the
blood-brain barrier, direct use of the intrathecal route allows lower
doses to be administered. The two other trials on CP investigated
the use of botulinum toxin A (BoNT-A) (Copeland 2014; Russo
2007). BoNT-A is primarily used, as described earlier, in CYP
with CP as an adjunct to other therapeutic techniques as a means
of reducing muscle tone and spasticity. It does this by blocking the
release of acetylcholine from the neuromuscular junction and so
weakening the muscle. The other four trials involved participants
with osteogenesis imperfecta (OI) (Bishop 2013; Letocha 2005;
Seikaly 2005; Ward 2011). OI is an inherited, primarily autoso-
mal dominant disorder of type I collagen that is characterised by
bone fragility and leads to a range of clinical expressions varying
in severity. All three trials evaluated the use of bisphosphonates
(two looked at oral alendronate (Seikaly 2005; Ward 2011), one
looked at oral risedronate (Bishop 2013) and the other at intra-
venous pamidronate (Letocha 2005)). Alendronate, pamidronate
and risedronate are types of bisphosphonate, a class of drugs that
prevent the loss of bone mass. Bisphosphonates inhibit the diges-
tion of bone by inactivating osteoclasts, the cells that break down
bone tissue, thereby slowing bone loss.
The ongoing trial was from the Netherlands. It is evaluating three
months of continuous intrathecal baclofen treatment in CP par-
ticipants compared with a placebo control (Bonouvrie 2013).
Cerebral palsy (CP)
Participants
The five studies on CP involved 105 participants. The types of
CP varied.
• One study (a pilot study) involved CYP aged 8 to 17 years
with dystonic CP, ICD-10 code: G80.3, and Gross Motor
Function Classification System (GMFCS) level V (Bonouvrie
2011).
• One study referred to the sample as just ’CP’, labelled for
this review as ’CP, unspecified’, ICD-10 code: G80.9; GMFCS
level V in 38 cases and IV in 3 cases (Copeland 2014).
• Two studies (using the same population) (Hoving 2007;
Hoving 2009) involved CYP with spastic tetraplegic cerebral
palsy, ICD-10 code: G80.0, Spastic diplegia cerebral palsy,
labelled in these studies as ’other CP’, G80.8 and dyskinetic
cerebral palsy, G80.3. One child was classified on the Gross
Motor Function Classification System at level III, two at level IV,
and 14 at level V.
• One study involved CYP with hemiplegic cerebral palsy,
labelled in this review as ’other CP’, ICD-10 code: G80.8, with
no mention of GMFCS level (Russo 2007).
The age range varied. In one study participants were 8 to 17 years
old (Bonouvrie 2011), in one study 2 to 16 years old (Copeland
2014), in two studies 7 to 16 years old (the same population)
(Hoving 2007; Hoving 2009) and in the other study 3 to 16 years
old (Russo 2007).
Setting
All studies were hospital based, three of which were multi-site
(Hoving 2007; Hoving 2009; Russo 2007) and two single-site
(Bonouvrie 2011; Copeland 2014).
Osteogenesis imperfecta (OI)
Participants
The four studies on OI involved 274 participants in total. There
are eight types of OI, I to VIII, all of varying severities. Pain in
OI may be due to bone destruction or associated deformity and
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therefore is likely to be of a mixed nature. Three studies (Bishop
2013; Seikaly 2005; Ward 2011) included CYP with a range of
OI types (I, II, III and IV) and one (Letocha 2005) included CYP
with types III and IV. The age range in the studies varied: 4 to 15
years old (Bishop 2013), 4 to 13 years old (Letocha 2005), 3 to
15 years old (Seikaly 2005) and 4 to 19 years old (Ward 2011).
Setting
All studies were hospital based, with two being multi-site (Bishop
2013; Ward 2011) and the others single-site (Letocha 2005;
Seikaly 2005).
Excluded studies
Most studies were excluded due to the lack of a comparator group
or not having pain outcomes, see the Characteristics of excluded
studies table.
Risk of bias in included studies
All trials were at some risk of bias, see Figure 2 and Figure 3. Three
were assessed as high risk in relation to blinding (Hoving 2009;
Letocha 2005; Russo 2007) and one in relation to attrition, 27%
(29/109) in the intervention group compared with 13% (4/26) in
the comparison group (Ward 2011).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study; + = study matched criteria, - = study did not match criteria, ? = unclear if study matched or did not
match the criteria.
12Pharmacological interventions for pain in children and adolescents with life-limiting conditions (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
Six trials adequately described randomisation sequence generation
(Bishop 2013; Hoving 2007; Hoving 2009; Letocha 2005; Russo
2007; Seikaly 2005) and five of these adequately described allo-
cation concealment (Bishop 2013; Hoving 2007; Hoving 2009;
Russo 2007; Seikaly 2005).
Blinding
Five trials were described as double-blind (Bishop 2013; Copeland
2014; Hoving 2007; Seikaly 2005; Ward 2011). Three of these
trials appeared to be at low risk of both performance and detection
bias (Bishop 2013; Copeland 2014; Seikaly 2005), in the other
two they did not state if the outcome assessor was blinded. One
trial was described as single-blind (Russo 2007). It used blinded
assessors for a subset of outcomes, but all other assessments per-
formed by the paediatric rehabilitation specialist were unblinded.
No placebo injections were administered in the control group due
to the requirement of general anaesthesia and so CYP and parents
were unblinded to their assignment group and could have revealed
this, making the trial high risk. One trial was labelled as unclear
as it did not mention blinding (Bonouvrie 2011), and two high
risk (Letocha 2005; Hoving 2009). In the Letocha 2005 trial in-
vestigators were blinded for vertebral area and compression mea-
sures only. Blinding of patients and their families was not possible
in the Hoving 2009 trial as CYP either received the intervention
delivered via a pump and standard care (of physiotherapy, speech
therapy and occupational therapy) or in the control group received
standard care only.
Incomplete outcome data
Four trials were low risk, either because few participants (Bishop
2013) were lost from the trial or they clearly stated the methods of
dealing with missing data (Copeland 2014; Letocha 2005; Russo
2007). Copeland used a two-group comparison on all participants
in an intention-to-treat analysis. The trial by Russo 2007 also used
an intention-to-treat analysis, the missing data were reported and
were balanced across both arms of the trial; with the intention-
to-treat analysis the missing data were unlikely to have affected
the results. Letocha used a per protocol and repeated-measures
model of analysis. One trial was deemed high risk (Ward 2011)
as although they used intention-to-treat analysis, the previous on-
treatment observation was carried forward for the missing data
and the number lost to follow-up (and number of adverse events)
was much higher in the treatment group (27% (29/109) versus
13% (4/26)). The reasons for missing outcome data may be re-
lated to true outcome and the pain may be higher in those who
did not return. Four trials were labelled as unclear (Bonouvrie
2011; Hoving 2007; Hoving 2009; Seikaly 2005). In the trial by
Bonouvrie 2011 analysis or incomplete data were unclear and data
were only completed for two of the four participants. The missing
data in the Hoving 2007 trial were unclear with no reasons pro-
vided except the fact that they excluded one male due to use of
open label medications and the authors reported deviating from
the protocol by starting with a lower dose for one participant.
There were no details in the Hoving 2009 trial about missing data
or how these would be dealt with. In the Seikaly 2005 trial only
17 participants completed the two year study and it was not clear
why three participants dropped out.
Selective reporting
Eight of the trials did not cite or refer to a protocol for the reader to
assess what the planned outcomes were intended to be, and so the
risk of selective reporting was unclear (Bishop 2013; Bonouvrie
2011; Hoving 2007; Hoving 2009; Letocha 2005; Russo 2007;
Seikaly 2005; Ward 2011). Only one trial referred to a protocol
for the trial which clearly laid out planned outcomes and so was
low risk (Copeland 2014).
Other potential sources of bias
Two trials were deemed high risk (Bonouvrie 2011; Russo 2007).
In the study in which only two participants completed the study,
two ended the study prematurely and the trial period was ham-
pered by serious complicationsmaking it high risk for other sources
of bias (Bonouvrie 2011). In the other study there was no placebo,
only standard therapy, and so other biases could have affected this
trial (Russo 2007). Two trials were low risk (Copeland 2014;Ward
2011). In both trials the baseline characteristics appeared balanced
and the trials did not stop early. Four trials were labelled unclear
(Hoving 2007; Hoving 2009; Letocha 2005; Seikaly 2005). In
the Hoving trials they reported that results were confined to rela-
tively older CYPwith intractable spastic CPwho relied onwheeled
mobility (Hoving 2009). In the Letocha 2005 trial no informa-
tion was provided on the gender of CYP or exactly what the con-
trol group received (no placebo), and so unclear sample bias was
present. Lastly, in the Seikaly 2005 trial some outcomes excluded
CYP with type I OI and so the trial only reflected types III and
IV, but the authors did not explain why.
Effects of interventions
Cerebral palsy (CP)
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Intrathecal baclofen versus placebo or therapy as normal
Three small trials (of two populations) of CYP (aged 7 to 17 years)
with CP evaluated intrathecal baclofen (ITB) versus intrathecal
placebo (Bonouvrie 2011; Hoving 2007) or standard therapy (in-
cluding any physiotherapy, speech therapy and occupational ther-
apy) (Hoving 2009).
Pain
In two studies (Hoving 2007; Hoving 2009) pain was evaluated
as a primary outcome emerging from the individually formulated
problems and being separately analysed by a visual analogue scale
(VAS) (0 to 10) rated either by the patients themselves, if they had
sufficient ability to do so, or by their parents.
In the other trial pain was evaluated as a secondary outcome and
measured by a VAS (Bonouvrie 2011).
In one trial of 17 CYP (mean age 13 years, range 7 to 16) they
found that painmeasured using a VAS improved significantly after
administration of the drug in the intervention group compared
to standard therapy in the control group (MD 4.20, 95% CI
2.15 to 6.25) (Hoving 2009). In the same study population, at
6 months bodily pain or discomfort measured using the domain
score of the Child Health Questionnaire-Parent Form 50 (CHQ-
PF50) improved in the intervention group (MD 26.60, 95% CI
2.61 to 50.59). Likewise, at this time point there was a significant
difference comparing pain scores using the VAS in the ITB group
when compared with placebo (MD 4.20, 95% CI 2.15 to 6.26)
(Hoving 2007).
The other trial on ITB involved four CYP (aged 8, 9, 14 and
17 years). Compared with blinded placebo treatment, pain scores
increased 0.5 points during blinded ITB treatment and pain scores
were 2.6 points lower than at baseline (Bonouvrie 2011).
Safety
Trials reported safety measures, these were: number of adverse ef-
fects experienced, what the effects were, and the number of pa-
tients who dropped out due to adverse effects. Some of the ad-
verse effects were related to the procedure or device for administra-
tion, and none were related to the intervention drug administered.
Whilst all trials reported safety measures, Hoving 2009 reported
these six months after the end of the trial. At this time point those
in the control group would have also received the intervention (as
a wait-list control).
Nine adverse effects of ITB were registered in eight participants
in the Hoving 2007 trial of 17 CYP, and they mostly related to
lowered cerebrospinal fluid (CSF) pressure for example lethargy.
Fourteen of the 17 participants in Hoving 2009 experienced a
total of 51 non-procedure or device related adverse effects; again,
the most frequently observed event was lethargy. Fourteen of the
17 participants also experienced a total of 29 procedure or device
related adverse events, most were related to swelling at the pump
site (Hoving 2009).
The most common adverse effect in two trials, irrespective of
trial arm, was CSF leakage (Bonouvrie 2011; Hoving 2007). In
Bonouvrie 2011 this occurred in two patients in the ITB group,
which resulted in headache, nausea, the blinded trial phase to be
discontinued in one patient and in an extended hospital admission
in the other patient. CSF leakage from the catheter connection
occurred in three participants in Hoving 2007. In one of these,
the catheter connection was defective and a new catheter was in-
serted; in the other two the cap was reconnected. Five of the 51
non-procedure or device related adverse events in Hoving 2009
were considered as serious as they resulted in significant disability.
These were: difficulty swallowing, dysarthria, excessive hypotonia
in two cases and epileptic seizure. It was not clear whether the non-
procedure or device related serious adverse events were in those
who received the intervention or in those in the control group.
Three of the 29 procedure related events were considered serious,
these were: incomplete operation, abrupt lack of ITB effect and
pain at the pump site; all resulted in a prolonged hospital stay
(Hoving 2009). None of the participants in either of the Hov-
ing trials dropped out because of adverse effects (Hoving 2007;
Hoving 2009).
Other outcomes
Other main outcomes in the trials were:
• three main problems in daily care, dressing and speaking
(using VAS), changes in dystonia (using the Barry-Albright
Dystonia (BAD) scale) and comfort and happiness (both using
VAS) (Bonouvrie 2011);
• individually formulated problems (comprising of pain (see
results above) and ease of care such as operating a wheelchair)
(Hoving 2007; Hoving 2009);
• health related quality of life on self-care capability (using
the Caregiver Assistance Scale of the Pediatric Evaluation of
Disability Inventory self-care domain (PEDI)) (Hoving 2009);
• spasticity (using the Ashworth scale) (Hoving 2007).
Hoving 2007 found ease of care significantly improved in the ITB
group compared with the placebo group (MD.10, 95%CI 2.52 to
5.68). In the same trial spasticity was found to improve at 2, 4 and
6 hours after administration of the intervention drug for all muscle
groups apart from hip flexors at one time point. After administra-
tion of the placebo there were no significant changes from baseline
reported. The VAS for individual problems improved significantly
for the ITB group compared with the control arm (MD4.10, 95%
CI 2.67 to 5.53) (Hoving 2009). The six-month change score for
caregiver assistance did not significantly differ between the trial
arms. In their trial of four participants Bonouvrie 2011 found no
improvement in problems related to daily care or in dystonia dur-
ing the blinded placebo and ITB treatment. They found comfort
increased in both groups. Happiness scores decreased slightly dur-
ing blinded placebo although they were maintained in those who
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received ITB treatment. Dystonia did not improve in either trial
arm.
Botulinium toxin A or botulinium toxin A and occupational
therapy versus placebo or occupational therapy alone
Two trials of CYP with CP investigated botulinium toxin A
(BoNT-A). One trial compared the effect of intravenous BoNT-
A with a placebo in 41 CYP with a mean age of 7 years (range 2 to
16 years) (Copeland 2014). The other trial in 43 children with a
mean age of 8 years (range 7 to 9 years) compared localised injec-
tions of BoNT-A undertaken under anaesthetic plus occupational
therapy versus occupational therapy alone (Russo 2007).
Pain
Pain was evaluated in both trials as a secondary outcome: it
was measured by the Pediatric Pain Profile (PPP) in one study
(Copeland 2014) and the other used a VAS (0 to 5) (unclear if
parent or patient rated the pain) (Russo 2007). In one trial there
were no significant between group differences at 4 or 16 weeks
(MD -2.67, 95% CI -10.18 to 4.84; MD 2.59, 95% CI -3.75 to
8.93, respectively) (Copeland 2014). In the other trial no differ-
ences were found between the treatment arms in reporting pain at
3 and 6 months (2 participants in each group, OR 1.05, 95% CI
0.13 to 8.24; 1 participant in each group, OR 1.05, 95% CI 0.06
to 17.95, respectively) (Russo 2007).
Safety
In one trial of 43 participants two of the children in the control
group and one in the intervention group experienced an adverse
event (Russo 2007). In the control group this involved two hos-
pital admissions for seizures in one child with epilepsy and three
hospital admissions for medical reasons in another child. In the
intervention group, one adverse event was reported in a child with
epilepsy (this resulted in admission to hospital for seizure man-
agement shortly after injection). In the intervention group there
were a total of 22 adverse effects, the most frequent were feeling
unwell after the anaesthetic and excessive weakness in the injected
limb. No adverse effects were reported in the control group.
In the other trial on BoNT-A, of 41 participants three partici-
pants in the intervention group and one in the placebo group ex-
perienced an adverse event (Copeland 2014). In the intervention
group, one adverse eventwas systemic involving increased drooling
or decreased vocalization and was possibly related to the injection.
Another was neurologic, involving prolonged seizure resulting in
a five day hospital admission, and was unlikely to be related to
the injection. In the control group two adverse effects were respi-
ratory related (pneumonia 15 weeks post-injection, resulting in a
one day hospital admission, unlikely to be related to the injection;
and croup resulting in a one day hospital admission) and one was
gastroenterological (vomiting and diarrhoea, resulting in a six day
hospital admission, unlikely to be related to the injection). There
were also other effects reported for 23 participants that were de-
scribed as either moderate or mild, and significantly more par-
ticipants in the intervention group experienced these (OR 9.36,
95% CI 2.24 to 39.12). Moderate adverse events reported in both
trial arms included seizures and respiratory symptoms. In regards
to mild adverse events in the intervention group, most related to
bruising at the injection site.
Other outcomes
Other outcomes which were declared as primary outcomes in the
trials were: performance and satisfaction in areas of concern for
care and comfort using the Canadian Occupational Performance
Measure (COPM) (Copeland 2014) and activity participation (us-
ing the Assessment of Motor and Process Skills (AMPS) and the
Goal Attainment Scaling (GAS)) (Russo 2007).
The Copeland 2014 trial reported significant between group dif-
ferences favouring the BoNT-A-treated group on COPM perfor-
mance at 4 weeks (MD 2.2, 95% CI 0.8 to 3.5) and for COPM
satisfaction (MD 2.2, 95% CI 0.5 to 3.9). These effects were re-
tained at 16 weeks for COPM satisfaction (MD 1.8, 95% CI 0.1
to 3.5) but not for performance.
In Russo 2007 the intervention group improved significantly on
theGAS score for goal attainment at 3months but not at 6months
(MD 3.00, 95% CI 5.31 to 20.69; MD 3.90, 95% CI -6.68 to
14.48, respectively). The difference between the groups on the
AMPS was not significant at 3 and 6 months (motor skills MD -
0.22, 95% CI -0.67 to 0.23; MD -0.15, 95% CI -0.65 to 0.35;
and process skills MD -0.14, 95% CI -0.63 to 0.35; MD -0.18,
95% CI -0.68 to 0.32, respectively).
Osteogenesis imperfecta (OI)
Oral alendronate versus placebo
Two trials investigated oral alendronate versus placebo (Seikaly
2005; Ward 2011).
Pain
Pain was evaluated in the Seikaly 2005 cross-over trial of 20 CYP
(mean age 9 years, range 3 to 15 years) as one of the primary out-
comes; it was measured by number of pain-free days per month,
and the number of days that analgesia was administered for skele-
tal pains. In the Ward 2011 trial of 139 CYP (mean age 11 years,
range 4 to 19 years) it was a secondary outcome; measured by the
number of patients with bone pain and the number of days per
week that the patients experienced bone pain. In the cross-over
trial a significant decrease favouring the intervention treatment
was found in pain scores and analgesic use at 12 months at the end
of the cross-over two-treatment periods (MD -3.63, 95%CI -5.17
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to -2.09; MD -2.00, 95% CI -3.57 to -0.43, respectively) (Seikaly
2005). In the other trial fewer patients receiving alendronate com-
pared to placebo (37% (38/102) versus 57% (17/30)) experienced
bone pain at 24 months but this was not statistically significant
(OR 0.45, 95% CI 0.20 to 1.04); there was no significant differ-
ence in the alendronate arm between baseline and follow-up in
the number of days per week during which patients suffered bone
pain (MD -0.73, 95% CI -4.69 to 3.23) (Ward 2011).
Safety
Twoof the 20 participants had adverse effects in the trial by Seikaly
2005, in the intervention group. The two participants developed
abdominal discomfort which was relieved after the child followed
instructions to stay upright for two hours after administration of
alendronate. No adverse events were reported.
In the other trial of 139 participants gastrointestinal symptoms
were also themost commonly experienced adverse event, occurring
in just over half of all participants in both trial arms (OR 1.23,
95% CI 0.47 to 3.23) (Ward 2011). For two alendronate patients
(1.8%) and one placebo patient (3.3%) a serious adverse event
resulted in withdrawal from the study; none were deemed to be
drug related by the study investigators (it was not described what
the serious adverse events were). Six patients in the alendronate
group withdrew from the study due to adverse events including
abdominal pain, vomiting, extraskeletal ossification, leukopenia,
agitation and syringomyelia or platybasia. Only the abdominal
pain and vomiting were attributed to the study drug. The trial
did not state whether any participants withdrew from the placebo
group.
Other outcomes
Other outcomes reported in both trials includedbonemineral den-
sity (BMD) (measured by BMD DEXA Z scores) (Seikaly 2005;
Ward 2011). The primary outcome in the Ward 2011 trial was
changes in lumber vertebrae BMD. The Seikaly 2005 trial also
investigated quality of life: self-care (measured using the WeeFIM
system 18-item tool that measures performance in essential daily
activities), mobility (using the modified Pediatric Evaluation of
Disability Inventor (PEDI)) and well-being (using self-reported
scores 1 to 10). Secondary outcomes included: physical evalua-
tion, food records, blood and urine analysis, stool guaiac, renal
ultrasound, skeletal survey (including rate of fractures).
The Seikaly 2005 trial reported a significant increase in BMD
Z score, 0.89 with alendronate compared to -0.12 with placebo
(MD 1.01, 95% CI 0.55 to 1.47). Significant improvement was
observed in well-being scores (MD 3.19, 95% CI 2.25 to 4.13)
and an increase in self-care with alendronate versus placebo (MD
3.58, 95%CI1.06 to 6.10), but no improvements inmobilitywere
observed. No changes were observed in the secondary outcomes
apart from cross-linked N-telopeptide of type 1 collagen divided
by urinary creatinine (uNTX/uCr) which decreased by 56% after
1 year of alendronate therapy, but the decrease in the frequency of
bone fractureswas not significant. In the other trial the alendronate
group had a significant increase in lumbar spine BMD Z score at
24 months (MD 1.18, 95% CI 0.90 to 1.46) (Ward 2011).
Oral risedronate versus placebo
One trial of CYP investigated oral risedronate versus a placebo
(Bishop 2013).
Pain
Pain evaluationwas not themain focus of this trial. It was evaluated
using pain scales (type not noted) and as an adverse event. The
trial reported in its discussion section that there was no difference
in pain scales between the trial arms.
Safety
There was no difference between the trial arms in the safety profile,
including the number of children experiencing adverse events (OR
0.46, 95%CI 0.09 to 2.24).When pain was reported as an adverse
event there was also no significant difference between the trial
arms in the number of participants experiencing pain (OR 1.54,
95% CI 0.52 to 4.56). There were two serious adverse events
that were possibly or probably study related. Both occurred in
the intervention group but the authors did not describe what the
events were. One patient on risedronate withdrew because of an
adverse event; this was Crohn’s disease, which was believed by the
investigators to be possibly related to the study drug.
Other outcomes
Other outcomes reported were lumber spine and total body areal
BMD Z scores and clinical fractures. Using an ANCOVA model
with fixed effects for age, treatment and centre they found a sig-
nificant difference in lumber spine BMD Z score that favoured
those taking risedronate (at 6 and 12 months, P < 0.0001). There
were fewer non-vertebral fractures reported at one year follow-up
in those in the intervention group compared to control (OR 0.46,
95% CI 0.23 to 0.95). No children had a vertebral fracture. No
difference was found between the trial arms in total body BMD
Z score.
Intravenous pamidronate versus no treatment
control group
One trial of 18 CYP investigated intravenous pamidronate versus
a no treatment control group (Letocha 2005).
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Pain
Pain was evaluated as a secondary outcome, measured by a 4 point
self-reported pain scale (from 4 = no pain to 1 = intractable pain).
No changes in self-reported bone pain were found (MD -0.11,
95% CI -0.83 to 0.61).
Safety
All participants experienced acute phase reactions upon the first
infusion cycle of pamidronate. What these reactions were are not
described; no other complications were noted.
Other outcomes
The primary outcome in this trial was changes in bone density
(vertebral DXA Z score, height, and area) (Letocha 2005). Signif-
icant increases were observed in DXA Z score with pamidronate
at 6 months (MD 21.59, 95% CI 5.79 to 37.39) and at 12
months (MD 25.60, 95% CI 11.48 to 39.72). Increases in L1 to
L4 midvertebral height (P = 0.014) and total vertebral area (P =
0.003) were found compared with the controls. However, during
extended treatment (after the trial), DXA Z scores and vertebral
heights and areas did not increase significantly.
D I S C U S S I O N
Summary of main results
This review set out to consider the pharmacological interventions
evaluated for pain in CYP with LLCs. Whilst we identified nine
relevant studies, the primary objective of the pharmacological in-
tervention was not the treatment of pain in all studies (Bishop
2013; Bonouvrie 2011; Copeland 2014; Hoving 2007; Hoving
2009; Letocha 2005; Russo 2007; Seikaly 2005;Ward 2011). Nei-
ther was it in the ongoing trial that was identified (Bonouvrie
2013). Trial participants’ ages ranged from 3 to 19 years, with the
mean ages ranging from 8 to 11 years). Participants in trials had
been diagnosed with cerebral palsy (CP) in five of the studies and
osteogenesis imperfecta (OI) in the other four studies. All studies,
apart fromone cross-over trial, were parallel group designed RCTs.
Eligible studies evaluating pharmacological interventions for other
LLCs inCYPwere not found. There was heterogeneity in the eight
included trials and it was therefore not possible to combine their
outcome data in a meta-analysis. Pain measures were reported as
secondary outcomes in six studies (Bishop 2013; Bonouvrie 2011;
Copeland 2014; Letocha 2005; Russo 2007; Ward 2011). The
effects on pain for the different drugs in the differing populations
varied amongst the studies and are summarised below.
Intrathecal baclofen for pain in cerebral palsy (CP)
Two studies (using the same population, n = 17 participants) eval-
uated the use of intrathecal baclofen (ITB) for pain in CYP with
CP (Hoving 2007; Hoving 2009). One found no significant dif-
ference in pain between ITB and placebo (Hoving 2007). Both
found pain scores to significantly improve in the ITB arm com-
pared with the placebo group.
Intramuscular botulinum toxin A for pain in cerebral
palsy (CP)
In both trials pain was found to be not significantly different in
the botulinum toxin A (BoNT-A) group as compared to placebo
(Copeland 2014) or occupational therapy alone (Russo 2007).
Oral alendronate or risedronate for pain in
osteogenesis imperfecta (OI)
Three studies investigated the use of a bisphosphonate drug ad-
ministered orally; in two this was alendronate and in one rise-
dronate. One cross-over trial found a significant decrease in pain
in the alendronate group compared to placebo (Seikaly 2005).
There were no significantly different results for pain in the RCT
investigating alendronate compared to placebo (Ward 2011) or in
the RCT investigating risedronate compared to placebo (Bishop
2013).
Intravenous pamidronate for pain in osteogenesis
imperfecta (OI)
The RCT on pamidronate found no changes in bone pain in the
pamidronate group as compared to the no treatment control group
(Letocha 2005).
Safety and adverse events
In the ITB studies most of the adverse events were related to the
procedure or device for administration, these included swelling at
the pump site andCSF leakage from the catheter (Bonouvrie 2011;
Hoving 2007;Hoving 2009).Whilst these events are not related to
the intervention drug itself, it is recognised that the administration
is a risky procedure as it involves the central nervous system. The
events are important to highlight here because of their negative and
potentially serious impact on the patient. The adverse events in the
BoNT-A trials were sparse and mostly involved those participants
who received the intervention drug, where increased seizures were
reported in two participants with pre-existing epilepsy. Regarding
the bisphosphonates for OI, no adverse events were mentioned in
the pamidronate trial but in the alendronate trials gastrointestinal
problems seemed to be the most frequent adverse event in those
who received alendronate. No differences in adverse event profiles
were found in the trial arms in the risedronate study. There were
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serious adverse events in both arms, some of which may have been
study related. The authors provided no details on what they were,
apart from one person in the intervention arm leaving the study
because of Cohn’s disease.
Overall completeness and applicability of
evidence
In this review we found that published, controlled evidence about
the pharmacological interventions for pain in CYP with LLCs is
very limited. The evidence that is currently available from RCTs
has evaluated pain largely as a secondary outcome and the drugs
used were all adjuvants, not drugs which are used primarily for
pain. The drugs explored in the included studies may not be com-
monly used in general paediatric populations in palliative care pri-
marily for the management of pain (Himelstein 2006). Baclofen
is regularly used in paediatric practice to relieve muscle spasm and
associated pain, and may also be used as an adjuvant to other ther-
apies. Bisphosphonates are used frequently for managing pain in
specific circumstances such as conditions that cause osteoporosis
and painful bony metastasis. In general paediatric practice these
events are not common.
The generalisability of the review is extremely limited. Moreover,
the conditions explored in the included studies may not always
be considered life-limiting. OI is classified into a number of cat-
egories that vary in severity and prognosis. CP is a general term
used to describe a number of neurological conditions that affect
movement and co-ordination, and covers 10 different codes in the
Hain directory (Hain 2013). It is difficult to interpret the results
of the CP studies as the condition varies so widely in severity. CP
with uncontrolled and painful spasticity and OI of all types are
often treated in specialist tertiary clinical centres.
There is an extensive number of conditions included in the Hain
directory which are considered as life-limiting but for which we
found no evidence with respect to pain management, these in-
clude leukaemia, cystic fibrosis and congenital abnormalities. It
was striking to note the lack of studies of any methodological type
(RCT or other quantitative design) evaluating treatments for pain
in CYP for LLCs, such as NSAIDS and opioids. This is despite the
increasing prevalence of CYP with LLCs (Fraser 2012) and pain
being reported as a key symptom in a large proportion of condi-
tions (Beretta 2010; Bradshaw 2005; Feudtner 2011; Goldman
2006; Hechler 2008; Jalmsell 2006; Wolfe 2000). In particular,
we found no evidence on commonly used pain relief medications
recommended by WHO, such as opioids when pain is severe, nor
on the relative efficacy of differing routes of administration that
might meet differing clinical needs, for example in neonates, chil-
dren and adolescents with their varying capacities (WHO 2012).
Quality of the evidence
This review faced a number of difficulties in the quality of the ev-
idence identified. Apart from one larger trial which had 109 par-
ticipants in the treatment arm and 30 in the placebo arm (Ward
2011), all studies were small, with a maximum of 23 participants
in any treatment arm. Small sample size is a recurring issue in the
palliative care of CYP, partly due to the relative rarity of many
LLCs and also due to ethical and practical challenges to conduct-
ing research in this patient group. Use of cross-over trial method-
ology may enhance the investigation of the use of newly developed
drugs, where it may be deemed unethical to expose one group to
a potentially beneficial treatment and withhold it from another.
There are difficulties in defining LLCs in the palliative care of
CYP, and in this review we used the Hain directory of life-lim-
iting illnesses. The Hain directory provides a comprehensive list
of conditions, developed by experts in palliative care of CYP, and
has been used in a series of recent prevalence studies (Fraser 2012;
Fraser 2014). The Hain directory is subject to regular appraisal
and new additions are likely to be made in future updates. Of note
is that OI has only recently been added. There is also the problem
in palliative care of CYP of comparisons made across many diag-
nostic groupings (LLCs are heterogenous and so issues arise when
attempting to group them together). As recently found, not only
are LLCs increasing in incidence but non-malignant conditions
are more common than malignant conditions, and so research
needs to reflect this (Fraser 2014).
There are also difficulties in relation to the pharmacology of medi-
cations for pain as dosage and indication will vary across age ranges
of CYP. In the eight included studies in this review, no two studies
reported results for the same age range. Studies on the whole did
not use validated pain outcome measures. The use of outcomes
such as proxy VAS rather than a validated structured question-
naire is likely to introduce bias or heterogeneity and may preclude
potential future meta-analysis.
Only one trial (Copeland 2014) provided a protocol. Included
trials did not clearly report how missing data were handled, and
two were at high risk of biased results due to the dropout rate
of participants in one trial (Bonouvrie 2011) and the lack of a
placebo in another (Russo 2007). Four trials were labelled as un-
clear for other potential biases; these were generally due to a lack
of information about the placebo, exclusion criteria or sample bias
(Hoving 2007; Hoving 2009; Letocha 2005; Seikaly 2005).
Potential biases in the review process
The search strategy has strengths and limitations which impact
the review. We conducted a comprehensive database search, hand-
searched the bibliographies of key papers and contacted authors
when appropriate. Due to the long list of LLCs (as illustrated in
the Hain directory), it was decided to omit the condition element
from the terms used in our search strategy. This resulted in a higher
number of citations than many systematic reviews would screen.
Another limitation is that we excluded studies on perioperative
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pain and procedural pain, however this may have been linked to
a LLC in some CYP. Finally, in the review process we had two au-
thors completing the risk of bias tables (EB, VV), however for the
data extraction the first few trials were independently extracted by
two review authors and when a consensus was reached one author
(EB) continued to extract the trials and a second author verified
the data collection. This was rather than, as the protocol stated,
a second author duplicating the entire data collection. Because a
meta-analysis wasn’t conducted we decided that a second author
(LJ or BC) extracting the first few trials but verifying all the data
would be sufficient for the level of data extracted. In future ver-
sions of this review, should any more studies be identified we will
adopt duplicate independent data extraction.
Agreements and disagreements with other
studies or reviews
To our knowledge, no other systematic review including only
RCTs and controlled studies has been carried out solely to exam-
ine the effects of pharmacological interventions for pain in CYP
with LLCs. The WHO has conducted a systematic review on the
pharmacological treatment of persisting pain in CYP with medi-
cal illnesses which overlap with the current review (WHO 2012).
However, the WHO review focuses on pain in CYP with many
types of medical conditions not exclusively LLCs. It also uses evi-
dence not only restricted to RCTs. RCTs were reported from adult
studies and on postoperative pain but not in pharmacological in-
terventions for pain specifically in CYP with LLCs. In this re-
view trials were small and heterogeneous. We found substantial
heterogeneity between trials for pain outcomes, conditions and
the drugs used. Other Cochrane reviews have been conducted on
some overlapping topics. One review looked at BoNT-A and CP,
which found high level evidence supporting the use of BoNT-A
as an adjunct to managing the upper limb in CYP with spastic CP
but did not look specifically at pain as an outcome (Hoare 2010).
Another Cochrane review looked at OI and bisphosphonates and
their effectiveness in increasing BMD; it found that oral or intra-
venous bisphosphonates increase BMD in CYP and in adults with
OI but, like the current review, did not reveal any conclusions
about the effect the drugs had on pain (Phillipi 2008). A third
explored the effectiveness of transdermal fentanyl for cancer pain
(Hadley 2013). The review authors did not identify any studies in
children. From the evidence from nine studies they concluded, in
their implications for practice, that pain appeared to be improved
and the majority of patients would have no worse than mild pain.
However, these findings are subject to methodological weaknesses
in the original studies, including small sample sizes.
Research data on pain in children with chronic pain conditions
might be generalisable in considering specific pain mechanisms
or analgesic effects that are common to chronic pain and life-
limiting conditions. However, the research on pharmacological
interventions for children with chronic pain conditions is sparse
(Mathew 2014).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on current available data this systematic review is unable to
determine the effects of pharmacological interventions for pain for
CYP with LLCs. Our review provides limited evidence to guide
policy makers on the pharmacological interventions to use for re-
ducing pain in LLCs in CYP or to further inform clinicians on
their practice. Health providers and clinicians may consult the
WHOguidelines on Pharmacological Treatment of Persisting Pain
in ChildrenWith Medical Illnesses (WHO 2012) and the Associ-
ation for Paediatric Palliative medicine Master Formulary (APPM
2015). In the case of the WHO guidelines, for example, there are
19 clinical recommendations; these include when to use analgesic
treatment according to the child’s level of pain severity, and what
the medicines of choice are. In the absence of CYP studies these
have been based on expert guidance or clinician consensus and
clinical trial evidence from adult RCTs and studies in conditions
that are not life-limiting. Until more studies in CYP with LLCs
have been undertaken, this remains the best basis for pain man-
agement in this population.
Implications for research
Currently, there is a lack of evidence fromRCTs that solely examine
the effects of pharmacological interventions for pain for CYP with
LLCs. Clinical trials need to be conducted to inform clinicians’
practice. Trials need to specify clearly: 1) the target condition(s), 2)
the age range(s) of CYP, 3) the type of pain covered (nociceptive,
neuropathic, or both), 4) the best route of administration, and 5)
the most effective dosing schedule for different ages and weights.
Future trials should aim to examine the effects of the drugs with
larger populations and also be clear on methods for evaluating
pain (McGrath 2008).
As mentioned earlier, it would be interesting to know the different
types of routes of administration of drugs in CYP and which are
best to use in different age groups and varying conditions. Future
trials should also report methods of dealing with incomplete and
missing data, details on the placebo, and provide a detailed proto-
col to ensure selective reporting is not present. These details were
scarcely reported in the trials included in this review. Because of
the reasons mentioned in the quality of the evidence section, these
trials do have obstacles to overcome but with the rising prevalence
of many LLCs this becomes only more necessary.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bishop 2013
Methods Randomised placebo controlled parallel trial, multi-centre
Participants Children with osteogenesis imperfecta (OI) from 13 countries across North and South
America, Europe, Africa and Australia. Children had either a history of at east one non-
traumatic or low-impact fracture and an age-adjusted and sex adjusted areal BMD Z
score of -1.0 or less for either total body or lumber spine sites, or an adjusted areal BMD
Z score of -2.0 or less irrespective of a history of fractures
Interventions Route oral risedronate or placebo for 1 year. Children who weighed 10-30 kg received
2.5 mg risedronate or placebo daily, those who weighed more received 5 mg daily
Outcomes Height, absorptiometry scans of lumber spine and total body, clinical fractures were
reported as an adverse event and secondary outcome. Serum and urine samples for bone
turn over markers. Reports pain outcomes as adverse event
Notes Study funded by the pharmaceutical industry, the funders helped to obtain, analyse and
interpret the data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified by age (4 to 9 and 10 to 15 years)
children were randomised in a 2:1 ratio by
telephone-based interactive voice response
system in several permutated blocks of 10
to 12
Allocation concealment (selection bias) Low risk Stratified by age (4 to 9 and 10 to 15 years)
children were randomised in a 2:1 ratio by
telephone-based interactive voice response
system in several permutated blocks of 10
to 12
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study treatment was masked from pa-
tients, investigators and study personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study treatment was masked from pa-
tients, investigators and study personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk A total of 87/94 in the intervention group
and 49/49 in placebo group completed trial
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Bishop 2013 (Continued)
Selective reporting (reporting bias) Unclear risk Although not stated as a primary outcome
some of the findings on pain are reported
only in the discussion section
Other bias Unclear risk Conflicts of interest are declared in regards
to pharmaceutical funding
Bonouvrie 2011
Methods Single-centre double blind randomised case controlled trial
Participants 4 CYP were randomised. Age range: 8 to 17 years old, 3 male, 1 female. Cerebral palsy,
ICD-10: G80.3 (all Gross Motor Function Classification System level V)
Interventions A baseline observation period and a dose-finding period. After the baseline observation
period, an intrathecal catheter was introduced
Route: Intrathecal baclofen either continuously via the external micro-infusion pump or
in a daily bolus dosage in case of the external catheter and intrathecal placebo as control
Dose: The dosage was increased with approximately 25 micrograms per day until an
optimal dosage was found. The maximal dosage was 200 micrograms per day
Study period: All patients started with a trial period, in which they received ITB treat-
ment and had a dose finding period Then they were randomised into two groups, the
intervention or control group.The optimal dosage was maintained for at least three days.
After this period, the patients were randomised in two groups for blinded treatment and
received either ITBor intrathecal placebo treatment for four days.Hereafter, the intrathe-
cal catheter was removed. After the trial treatment, the patients, caregivers and doctors
decided, for or against implantation of a definite programmable pump (Medtronic) for
continuous ITB treatment
Outcomes Primary: Visual Analogue Scale (VAS) of ’three main problems of daily care’ (ascertained
before study via interview) “0” representing “no problems” and “10” representing “im-
possible to do”. Barry-Albright Dystonia (BAD) scale for dystonia
Secondary: Pain (of mixed origin) was assessed with a VAS, with “0” representing “no
pain” and “10” representing “very severe pain”, Comfort was assessed using a VAS (score
0 to 10), with a higher score representing more comfort) happiness was also assessed; very
sad looking face (score 1) to very happy looking face (score 5). Gross Motor Function
Classification System (GMFCS) and Pediatric Evaluation ofDisability Inventory (PEDI)
were only tested prior to starting the screening treatment
Notes Pilot study, only 2 participants completed the study
Financial assistance: Dr Phelps ”stichting voor spastici” (Project number: 99.047)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
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Bonouvrie 2011 (Continued)
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
High risk 2/4 CYP completed trial
Selective reporting (reporting bias) Unclear risk The abstract talks of results for all 4 partici-
pants when only 2 completed the study. No
protocol so unclear what outcomeswere in-
tended
Other bias High risk Only 2 participants completed the study, 2
ended the study prematurely. Trial period
hampered by serious complications
Copeland 2014
Methods Single-centre double-blind, randomised controlled trial with sham control
Participants 41 CYP randomised. Age range 2.3 to 16 years old, 27 male, 14 female. Cerebral palsy,
ICD-10: G80.8 (Gross Motor Function Classification System level IV = 3, level V = 38)
Interventions Route: Intravenous botulinum toxin A (BoNT-A) and placebo (saline injection then
ultrasound and blunt needle that doesn’t penetrate the skin)
Dose: 0.5 to 4 units Botox/kg/muscle group (Allergan PLC, Dublin, Ireland) as clinically
indicated to maximum dose of 12 U Botox/kg body weight (or total 400 units)
Study period: 16 weeks. Follow-ups were at baseline, 4 and 16 weeks
Muscle groups selected for injection were determined prior to randomisation and based
on parent’s or caregiver’s goals for improving ease of care and comfort in conjunction
with musculoskeletal assessment findings of hypertonicity
Outcomes Primary: Parent ratings in identified areas of concerns for their child’s care and comfort,
using the Canadian Occupational Performance Measure (COPM)
Secondary: Pain (of mixed origin) (using the paediatric pain profile), ease of care (Care
and Comfort Hypertonicity Questionnaire (CCHQ)), health status (measured using
the Caregiver Priorities and Child Health Index of Life with Disabilities [CPCHILD])
Questionnaire and quality of life (measured using the Cerebral Palsy Quality of Life
Questionnaire for Children (CPQOL-child))
Notes Protocol published (Thorley 2012)
Funding: AllerganAustralia PLC to the Royal Children’sHospital Foundation (Brisbane)
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Copeland 2014 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States that prior to randomisations, partic-
ipants will be stratified according to pri-
mary goal areas (upper limb or lower limb)
in order to allow block randomisation with
the intention that similar numbers of CYP
with predominantly upper and lower limbs
injected will be in each arm of the study.
No details on sequence generation
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, different clinicians con-
ducted procedures to the clinicians who
recorded results andparticipantswere blind
to the procedures
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A different physician conducted the proce-
dures (treatment injections and sham blunt
needle procedure) to the nurse that col-
lected the observations and was blinded to
the procedures so detection unlikely
Incomplete outcome data (attrition bias)
All outcomes
Low risk Uses two-group comparisons on all partic-
ipants on an intention-to-treat basis
Selective reporting (reporting bias) Low risk No selective outcome reporting present in
the study from assessing the outcomes in-
tended in the protocol
Other bias Low risk Baseline characteristics are quite balanced,
didn’t stop early, however the study may
be underpowered to detect some secondary
outcomes
Hoving 2007
Methods Multi-centre double-blind, randomised, placebo controlled trial
Participants 17 CYP randomised. Age range: 7 to 16, 9 females, 8 males. Cerebral palsy, G80.0, G80.
8, G80.3. One child was classified on the Gross Motor Function Classification System
at Level III, two at Level IV, and 14 at Level V
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Hoving 2007 (Continued)
Interventions Route: Intrathecally via the catheter baclofen or placebo was administered
Dose: During the first two test days the bolus randomly contained baclofen 25 µg or
placebo. On each of the subsequent six test days the bolus contained baclofen 50 µg or
placebo, then baclofen 75 µg or placebo, and, finally, baclofen 100 µg or placebo
Study period: 2 first test days then 6 subsequent test days (see above)
Outcomes Primary: Spasticity (measured by the original Ashworth scale and individually formulated
problems measured by visual analogue scale (VAS) (pain (of mixed origin) and ease of
care emerged from the individually formulated problems and were analysed separately
using VAS)
Notes Same participants as Hoving 2009. This is dose finding part of the trial
Three CYP in the CITB group and four in the Control group used oral baclofen
Funding: Research Fund of the University Hospital Maastricht and Medtronic Inc.,
Heerlen, the Netherlands. Medtronic Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Statistician generated randomisation lists
of patients order
Allocation concealment (selection bias) Low risk An independent statistician generated the
allocation and independent pharmacist
prepared the medication so the allocation
was concealed to the clinicians providing
the medication
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, clinicians involved in ad-
ministering themedication were blinded to
the contents of the study medication bo-
luses
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Pharmacist prepared placebo and treat-
ment boluses - everyone involved in
the study received numbered medica-
tion. However not stated that analyst was
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Themissing data is unclear with no reasons
provided except the fact they excluded one
male as performed open label on him (it
was not blinded)
Selective reporting (reporting bias) Unclear risk No information provided on protocol so
unclear
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Hoving 2007 (Continued)
Other bias Unclear risk Results are ’confined to relatively older
CYP with intractable spastic CP who rely
on wheeled mobility’ (Hoving 2009)
Hoving 2009
Methods Multi-centre non-blinded, randomised, placebo controlled trial
Participants 17 CYP randomised. Age range: 7 to 16 years, 9 females, 8 males. Cerebral palsy, G80.
0, G80.8, G80.3. One child was classified on the Gross Motor Function Classification
System at Level III, two at Level IV, and 14 at Level V
Interventions Route: Randomised to receive a programmable synchromed infusion pump (Medtronic,
Inc., Minneapolis, MN) of continuous intrathecal baclofen (CITB) after either 1 month
(CITB group) or 6 months (Control group who initially received intrathecal placebo),
standard therapy continued in both groups
Dose: Dose finding study previous study (Hoving 2007). Mean daily CITB dose was 67
µg (SD 25) right after pump implantation and 176 µg (SD 118) 6 months later
Study period: 6 months. Tested at baseline and then 6 months
Outcomes Primary - Caregiver assistance scale of the self care domain of the Pediatric Evaluation
of Disability Inventory (PEDI) and the visual analogue scale (VAS) for individually
formulated problems (ease of care and pain [of mixed origin] came out of the individually
formulated problems and were analysed separately using VAS)
Secondary - Body function and structure (measured by the original Ashworth scale),
capability (measured by the functional skills scale in the self-care domain of the PEDI)
and gross motor function (measured by the Gross Motor Function Measure (GMFM)),
health related quality of life (measured by the Child Health Questionnaire-Parent Form
50 (CHQ-PF50))
Notes Same participants as Hoving 2007
Three participants in the CITB group and four in the control group used oral baclofen
Funding: Research Fund of the University Hospital Maastricht and Medtronic Inc.,
Heerlen, the Netherlands. Medtronic Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Statistician generated randomisation lists
Allocation concealment (selection bias) Low risk The investigator who enrolled theCYP had
no entry to this list and was, at the time
of each enrolment, not aware of the next
assignment in the sequence. For assign-
ment, the investigator called the indepen-
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Hoving 2009 (Continued)
dent statistician who consulted the alloca-
tion list
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not possible as the interven-
tion was a pump inserted either one month
or 6 months after test treatment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding was not possible (see above)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data (no lost to follow-up
or discontinued intervention)
Selective reporting (reporting bias) Unclear risk No information provided on protocol so
unclear
Other bias Unclear risk Results are ’confined to relatively older
CYP with intractable spastic CP who rely
on wheeled mobility’
Letocha 2005
Methods Single-centre, non-blinded, randomised control trial. No placebo control
Participants 18 CYP were randomised. Age range: 4 to 13 years. Osteogenesis imperfecta type III
and IV included, ICD-10: Q78.0
Interventions Route: Intravenous pamidronate versus control (no treatment)
Dosage: 10 mg/m2/day for 3 days every 3 months
Study period: 12 months initially, then 7 participants in the treatment group were given
an additional 6 to 21 months of IV pamidronate
All participants were seen quarterly at the National Institutes of Health Clinical Center.
Serum markers of bone formation and growth parameters were measured at each visit.
Antero-posterior (AP) and lateral radiographs of the spine and lower extremity long
bones and DXA at vertebrae L1 to L4 were obtained at baseline and every 6 months.
QCT scans of the spine were performed at the National Institutes of Health Clinical
Center at 0 and 12 months
Outcomes Primary: Vertebral DXA Z score, height, and area
Secondary: Serum markers of bone formation, growth (length and sitting height to the
nearest 0.01 cm), Antero-posterior (AP) and lateral radiographs of the spine and lower
extremity long bones and DXA at vertebrae L1-L4, Upper and lower extremity fracture
rates, gross motor function (Brief Assessment of Motor Function (BAMF) scale) and
NIH functional assessment pain score (assessing pain likely to be of mixed origin)
Notes 4 participants in each group were receiving recombinant growth hormone (0.06 mg/kg/
day for 6 days/week)
Unclear what control group received
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Letocha 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomly generated numbers’
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded (blinded for vertebral area
and compression measures)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not completely blinded, investigators were
blinded for vertebral area and compression
measures
Incomplete outcome data (attrition bias)
All outcomes
Low risk A per protocol and repeated-measures
model of analysis was used, no incomplete
data
Selective reporting (reporting bias) Unclear risk No information provided on then protocol
so unclear
Other bias Unclear risk No information on gender of participants
or what the control group received (no
placebo), unclear sample bias
Russo 2007
Methods A multi centre, single-blind randomised controlled trial. Standard therapy control
Participants 43 CYP randomised. Age range: 3 to 16 years, 23 male, 20 female. Hemiplegic cerebral
palsy, ICD-10: G80.8
Interventions Route: Treatment Group (botulinum toxin A (BoNT-A) localised injections and occu-
pational therapy) and control - received the standardised occupational therapy program
only (no placebo injections)
Dose: The maximal dose of BTX-A per muscle according to Russman et al 1997 was
followed; however, all of the muscles across the upper limb were injected if tone was
affected. Total injected dose did not exceed 12 U/kg of body weight, to a maximum
dose of 300 U of Botox (Allergan, Australia Pty Ltd). The intervention was given under
anaesthetic
Study period: 6 months. Localised injections of BTX-A into the affected upper limb and
weekly occupational therapy for 4 weeks, follow-ups at 1 month (Assessment of Motor
and Process Skills, Goal Attainment Scaling, pain scale), 3 and 6 months
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Russo 2007 (Continued)
Outcomes Primary: Activity participation (measured by Assessment of Motor and Process Skills
[AMPS], and Goal Attainment Scaling (GAS))
Secondary: Body structure (measured using modified Ashworth Scale and the modified
Tardieu Scale), self-perception (using the Self Perception Profile for Children (older
children) and the Pictorial Scale of Perceived Competence and Social Acceptance for
Young Children), activity participation (using the Pediatric Evaluation of Disability
Inventory (PEDI) - Self care domain), quality of life (using the Pediatric Quality of
Life Scale), pain (likely to be of mixed origin) (using a visual analogue scale (VAS)) and
subjective function and cosmesis rating (same, better or worse since the intervention)
Notes Funding: Financial Markets Foundation for Children and Allergan Australia Pty Ltd
The authors kindly provided raw data from their study on pain outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated table of random
numbers
Allocation concealment (selection bias) Low risk Random assignment schedule and en-
velopes (concealed, opaque, and foil lined)
were prepared by an independent statisti-
cian
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single-blind, principle outcome measures
were functional measures and assessments
were blinded, but all of the assessments
performed by the paediatric rehabilitation
specialist were unblinded and no placebo
injections were administered in the con-
trol group due to the requirement of gen-
eral anaesthesia. CYP and parents were un-
blinded and knew their assignment group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Used blinded assessors for a subset of out-
comes (all outcomes except for MTS and
MAS). But participants and parents knew
their assignment group and could have re-
vealed this
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analyses were on an intention-to-treat ba-
sis. 3 refused intervention: 2 treatment, 1
control but took part in follow up, low risk
due to missing data balanced on both arms
of the trial and with intention to treat anal-
ysis, missing data is unlikely to affect results
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Russo 2007 (Continued)
Selective reporting (reporting bias) Unclear risk No information provided on protocol so
unclear
Other bias High risk No placebo, only standard therapy (no par-
ticipants received no therapy)
Seikaly 2005
Methods Single-centre double-blinded, placebo controlled cross-over trial
Participants 20 CYP randomised. Age range: 3 to 15 years, 11 males. Osteogenesis imperfecta types
I, III and IV. ICD-10: Q78.0
Interventions Route: Oral alendronate versus placebo
Dose: 5 mg/day (participants who weighed < 30 kg); or 10 mg/day (participants who
weighed > 30 kg) administered orally with at least 8 ounces of water, 30 minutes before
food intake; patients were also advised to maintain the upright position for at least 30
minutes after ingestion of the medication to reduce the chance of oesophageal irritation.
All subjects were maintained on a diet with adequate daily calcium (1000 to 1300 mg/
d), phosphorus (800 to 1200 mg/d), and vitamin D (400 IU/d) intake, at least 100%
daily referenced intake (DRI)
Study period: Participants were evaluated at baseline, then every 3 months (except when
otherwise indicated), and at the conclusion of the study (2 years)
Outcomes Primary: bone mineral density (BMD) (measured by BMD DEXA Z scores) and QoL-
functional abilities, mobility (using the modified Pediatric Evaluation of Disability In-
ventor (PEDI)), self-care score (using the WeeFIM system), well-being scores (1 to 10)
and pain (likely to be nociceptive rather than neurogenic but possibly of mixed origin)
including number of pain free days per month and number of days that analgesia was
administered for skeletal pains (parents were asked these two questions too)
Secondary: Physical evaluation, food records, blood and urine analysis, stool guaiac, renal
ultrasound, skeletal survey
Notes 17 participants completed the study
2 CYP with type I OI were excluded from the QoL analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer generated
(SAS 6.12). Included two period cross-over
Allocation concealment (selection bias) Low risk Pharmacist at institution assigned groups
so allocation was concealed from those in-
volved
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Seikaly 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: other members of the re-
search team were blinded to treatment un-
til data analysis, and participants blinded
too
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unlikely to be detected as research team
assessing outcomes were blinded and ra-
diologists detecting the fractures were also
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Repeatedmeasures analysis of variance. 17/
20 participants completed the 2 year study
(unclear why dropped out)
Selective reporting (reporting bias) Unclear risk No information provided on the protocol
so unclear
Other bias Unclear risk Some outcomes excluded CYP with type
I OI and so only reflect types III and IV,
unclear why
Ward 2011
Methods Multi-centre randomised, double blind, parallel-group, placebo-controlled study
Participants 139 CYP were randomised. Age range: 4 to 19 years, 78 male, 61 female.Type I, III, or
IV osteogenesis imperfecta, ICD-10: Q78.0
Interventions Route: Oral alendronate versus placebo
Dose: Alendronate doses were 5 mg/day in participants weighing less than 40 kg and
10 mg/day for those weighing 40 kg and greater. In younger participants weighing less
than 40 kg the dose was halved
Study period: 24 months (follow ups every 3 months)
Outcomes Primary: The change in LS (lumbar vertebrae 1 to 4) area lBMD z-score
Secondary: Pain (likely to be of mixed origin) measured by number of patients with
bone pain and number of days per week patients experience bone pain, cortical width
determined radiographically at the midpoint of the second metacarpal, the number of
radiologically confirmed fractures, the number of investigator-reported fractures, and
the change in cortical width of iliac bone determined by transiliac biopsy. Change from
baseline in body mass index z-score, and change from baseline in the relative amount of
unmineralized osteoid in trabecular bone. In addition, a variety of clinical, radiological,
and biochemical outcome variables were assessed
Notes Financial assistance: Merck Research Laboratories, Whitehouse Station (NJ). LMW is
supported by a New Investigator Award through the Canadian Institutes for Health
Research and a Career Development Award by the Canadian Child Health Clinician
Scientist Program. Disclosure Statement: LMW has received more than $10,000 as
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Ward 2011 (Continued)
a consultant to Novartis; F.H.G. has received more than $10,000 as Merck principal
investigator; MPW owns stocks/stock options less than $10,000 in Merck; NV, NH,
and AL are employees of Merck, Co. Inc. and own stocks valued at $10,000 or more in
Merck
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was 3:1 ALM to placebo
and stratified according to weight at base-
line. No other information stated
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind- evaluate by radiologists who
were blinded to treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
High risk For missing data, the previous on-treat-
ment observation was carried forward”.
Used “intention-to-treat” analysis. The
number lost to follow-up (and number of
adverse events) is higher in the ALN group,
27% (29/109) versus 13% (4/26)
Reason for missing outcome data may be
related to true outcome e.g. pain score. The
pain may be higher in those who did not
return
Selective reporting (reporting bias) Unclear risk No information provided on protocol so
unclear
Other bias Low risk Baseline characteristics appear balanced;
didn’t stop early
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adiyaman 2004 The study had no comparator
Alvarez Lopez 2002 Case study only
Andiran 2008 The study had no comparator
Astrom 1998 The study had no comparator
Astrom 2002 The study had no comparator
Astrom 2010 The study had no comparator
Banerjee 2002 The study had no comparator
Barros 2012 The study had no pain outcomes
Bhadada 2009 The study had no comparator
Darnell 2008 The author could not access the data
DiMeglio 2005 The study had no pain outcomes
DiMeglio 2006 The study had no pain outcomes
Dominguez-Bartmess 2012 Not a life-limiting condition
Falk 2003 The study had no comparator
Finkel 2005 The study had no comparator
Forin 2005 The study had no comparator
Gatti 2005 The study had no pain outcomes
Glorieux 1998 The study had no comparator
Gonzalez 2001 The study had no comparator
Hoving 2006 The study had no pain outcomes
Hoving 2008 The study had no comparator
Jakubowska 2008 The study had no comparator
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(Continued)
Kokavec 2008 The study had no comparator
Land 2007 The study had no comparator
Morris 2013 Whilst disease is life-limiting, it is not necessary life limited in childhood or as a young person
Plotkin 2000 No data on pain outcomes (tried contacting authors)
Pressac 2002 The study had no comparator
Rauch 2009 OI type I (mildest form of OI) so not LLC
Ruggiero 2007 The study had no comparator
Ruggiero 2013 The study had no comparator
Saarenmaa 1999 Not enough of sample had a LLC, data not broken down, tried to contact author for raw data
Sakkers 2004 The study had no pain outcomes
Salehpour 2010 The study had no comparator
Sanger 2007 The study had no comparator
Van Schaeybroeck 2000 Sample includes only one child
Ward 2005 The study had no pain outcomes
Zeitlin 2003 The study had no comparator
Characteristics of ongoing studies [ordered by study ID]
Bonouvrie 2013
Trial name or title The IDYS trial
Methods RCT
Participants Patients aged 4 to 25 years with confirmed diagnosis of dystonic cerebral palsy
Interventions Group 1: 3 months of continuous intrathecal baclofen treatment, Group 2: placebo
Outcomes Primary: activities of daily living. Secondary: body functions, spasticity, pain, comfort and sleep-related
breathing disorders
38Pharmacological interventions for pain in children and adolescents with life-limiting conditions (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bonouvrie 2013 (Continued)
Starting date Not stated
Contact information NTR3642
Notes
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL (the Cochrane Library)
#1 MeSH descriptor: [Pain] explode all trees
#2 MeSH descriptor: [Pain Management] this term only
#3 (pain* or headache* or migraine* or neuralgia or neuropathic):ti,ab,kw (Word variations have been searched)
#4 #1 or #2 or #3
#5 MeSH descriptor: [Analgesics] explode all trees
#6 MeSH descriptor: [Anesthesia, Local] this term only
#7 MeSH descriptor: [Anticonvulsants] explode all trees
#8 MeSH descriptor: [Antidepressive Agents] explode all trees
#9 MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees
#10 MeSH descriptor: [Muscle Relaxants, Central] explode all trees
#11 MeSH descriptor: [Parasympatholytics] explode all trees
#12 MeSH descriptor: [Serotonin Uptake Inhibitors] explode all trees
#13 MeSH descriptor: [Steroids] explode all trees
#14 (acetaminophen or “acetylsalicylic acid” or “alendronic acid” or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or “choline magnesium trisalicylate” or clonazepam
or clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or
diazepam or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone
or “hyoscine hydrobromide” or ibuprofen or ketamine or ketoprofen or ketorolac or “levo bupivacaine” or lidocaine or loperamide
or lorazepam or mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous
oxide or nortriptyline or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or
“phenytoin” or piroxicam or pregabalin or propoxyphene or “risedronate sodium” or “sodium clodronate” or tetracaine or tramadol or
“valproic acid”):ti,ab,kw (Word variations have been searched)
#15 #5 or #6 or #7 or #8 or #9 or #10 or #11 or 12 or #13 or #14
#16 MeSH descriptor: [Infant] explode all trees
#17 MeSH descriptor: [Child] explode all trees
#18 MeSH descriptor: [Adolescent] this term only
#19 (neonate* or newborn or infant* or child* or adolescen* or paediatric* or pediatric* or baby or babies or toddler* or teen* or
juvenile* or boy* or girl*):ti,ab,kw (Word variations have been searched)
#20 #16 or #17 or #18 or #19
#21 #4 and #15 and #20
MEDLINE (Ovid)
1. exp Pain/
2. Pain Management/
3. (pain* or headache* or migraine* or neuralgia or neuropathic).mp.
4. or/1-3
5. exp Analgesics/
6. Anesthesia, Local/
7. exp Anticonvulsants/
8. exp Antidepressive Agents/
9. exp Anti-Inflammatory Agents, Non-Steroidal/
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10. exp Muscle Relaxants, Central/
11. exp Parasympatholytics/
12. exp Serotonin Uptake Inhibitors/
13. exp Steroids/
14. (acetaminophen or “acetylsalicylic acid” or “alendronic acid” or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or “choline magnesium trisalicylate” or clonazepam
or clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or
diazepam or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone
or “hyoscine hydrobromide” or ibuprofen or ketamine or ketoprofen or ketorolac or “levo bupivacaine” or lidocaine or loperamide
or lorazepam or mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous
oxide or nortriptyline or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or
“phenytoin” or piroxicam or pregabalin or propoxyphene or “risedronate sodium” or “sodium clodronate” or tetracaine or tramadol or
“valproic acid”).mp.
15. or/5-14
16. exp Infant/
17. exp Child/
18. Adolescent/
19. (neonate* or newborn or infant* or child* or adolescen* or paediatric* or pediatric* or baby or babies or toddler* or teen* or
juvenile* or boy* or girl*).mp.
20. 16 or 17 or 18 or 19
21. 4 and 15 and 20
22. clinical trial/
23. n of 1 stud*.mp.
24. ((single case or single-case) adj (report* or stud*)).mp. [mp=title, abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
25. (“comparator group*” or “comparision group*”).mp. [mp=title, abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
26. or/22-25
27. randomized controlled trial.pt.
28. controlled clinical trial.pt.
29. randomized.ab.
30. placebo.ab.
31. drug therapy.fs.
32. randomly.ab.
33. trial.ab.
34. or/27-33
35. exp animals/ not humans.sh.
36. 34 not 35
37. 26 or 36
38. (animal/ or nonhuman/) not human/
39. 37 not 38
40. 21 and 39
41. limit 40 to (“newborn infant (birth to 1 month)” or “infant (1 to 23 months)” or “preschool child (2 to 5 years)” or “child (6 to
12 years)” or “adolescent (13 to 18 years)”)
EMBASE (Ovid)
1. exp Pain/
2. Pain Management/
3. (pain* or headache* or migraine* or neuralgia or neuropathic).mp.
4. or/1-3
5. exp Analgesics/
6. Anesthesia, Local/
7. exp Anticonvulsants/
8. exp Antidepressive Agents/
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9. exp Anti-Inflammatory Agents, Non-Steroidal/
10. exp Muscle Relaxants, Central/
11. exp Parasympatholytics/
12. exp Serotonin Uptake Inhibitors/
13. exp Steroids/
14. or/5-14
15. exp Pain/
16. Pain Management/
17. (pain* or headache* or migraine* or neuralgia or neuropathic).mp.
18. or/15-17
19. exp Analgesics/
20. Anesthesia, Local/
21. exp Anticonvulsants/
22. exp Antidepressive Agents/
23. exp Anti-Inflammatory Agents, Non-Steroidal/
24. exp Muscle Relaxants, Central/
25. exp Parasympatholytics/
26. exp Serotonin Uptake Inhibitors/
27. exp Steroids/
28. (acetaminophen or “acetylsalicylic acid” or “alendronic acid” or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or “choline magnesium trisalicylate” or clonazepam
or clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or
diazepam or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone
or “hyoscine hydrobromide” or ibuprofen or ketamine or ketoprofen or ketorolac or “levo bupivacaine” or lidocaine or loperamide
or lorazepam or mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous
oxide or nortriptyline or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or
“phenytoin” or piroxicam or pregabalin or propoxyphene or “risedronate sodium” or “sodium clodronate” or tetracaine or tramadol or
“valproic acid”).mp.
29. or/19-28
30. exp Infant/
31. exp Child/
32. Adolescent/
33. (neonate* or newborn or infant* or child* or adolescen* or paediatric* or pediatric* or baby or babies or toddler* or teen* or
juvenile* or boy* or girl*).mp.
34. 30 or 31 or 32 or 33
35. 18 and 29 and 34
36. random$.tw.
37. factorial$.tw.
38. crossover$.tw.
39. cross over$.tw.
40. cross-over$.tw.
41. placebo$.tw.
42. (doubl$ adj blind$).tw.
43. (singl$ adj blind$).tw.
44. assign$.tw.
45. allocat$.tw.
46. volunteer$.tw.
47. Crossover Procedure/
48. double-blind procedure.tw.
49. Randomized Controlled Trial/
50. Single Blind Procedure/
51. or/36-50
52. clinical trial/
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53. time series analysis/
54. n of 1 stud*.mp.
55. ((single case or single-case) adj (report* or stud*)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
56. (“comparator group*” or “comparision group*”).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
57. 52 or 53 or 54 or 55 or 56
58. 51 or 57
59. (animal/ or nonhuman/) not human/
60. 58 not 59
61. 35 and 60
PsycINFO (Ovid)
1. exp Pain/
2. Pain Management/
3. (pain* or headache* or migraine* or neuralgia or neuropathic).mp.
4. or/1-3
5. exp analgesic drugs/
6. Local anesthetics/
7. exp Anticonvulsive drugs/
8. exp Antidepressant drugs/
9. exp Anti inflammatory drugs/
10. exp Muscle Relaxing drugs/
11. exp Serotonin Uptake Inhibitors/
12. exp Steroids/
13. (acetaminophen or “acetylsalicylic acid” or “alendronic acid” or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or “choline magnesium trisalicylate” or clonazepam
or clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or
diazepam or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone
or “hyoscine hydrobromide” or ibuprofen or ketamine or ketoprofen or ketorolac or “levo bupivacaine” or lidocaine or loperamide
or lorazepam or mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous
oxide or nortriptyline or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or
“phenytoin” or piroxicam or pregabalin or propoxyphene or “risedronate sodium” or “sodium clodronate” or tetracaine or tramadol or
“valproic acid”).mp.
14. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15. (neonate* or newborn or infant* or child* or adolescen* or paediatric* or pediatric* or baby or babies or toddler* or teen* or
juvenile* or boy* or girl*).mp.
16. 4 and 14 and 15
17. clinical trials/
18. (randomis* or randomiz*).tw.
19. (random$ adj3 (allocat$ or assign$)).tw.
20. ((clinic$ or control$) adj trial$).tw.
21. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
22. (crossover$ or “cross over$”).tw.
23. random sampling/
24. Experiment Controls/
25. Placebo/
26. placebo$.tw.
27. exp program evaluation/
28. treatment effectiveness evaluation/
29. ((effectiveness or evaluat$) adj3 (stud$ or research$)).tw.
30. or/17-29
31. 16 and 30
32. exp Time Series/
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33. n of 1 stud*.mp.
34. ((single case or single-case) adj (report* or stud*)).mp.
35. (“comparator group*” or “comparision group*”).mp.
36. or/32-35
37. 36 and 16
38. 37 or 31
CINAHL (EBSCO)
S39 S38 or S31
S38 (S21 AND S37)
S37 S32 OR S33 OR S34 OR S35 OR S36
S36 (“comparator group*” or “comparision group*”)
S35 ((single case or single-case) N1 (report* or stud*))
S34 n of 1 stud*
S33 (MH “Time Series”)
S32 (MH “Clinical Trials”)
S31 S21 AND S30
S30 S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29
S29 (allocat* random*)
S28 (MH “Quantitative Studies”)
S27 (MH “Placebos”)
S26 placebo*
S25 (random* allocat*)
S24 (MH “Random Assignment”)
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S23 (Randomi?ed control* trial*)
S22 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or
(singl* mask* )
S21 S4 AND S15 AND S20
S20 S16 OR S17 OR S18 OR S19
S19 (neonate* or newborn or infant* or child* or adolescen* or paediatric* or pediatric* or baby or babies or toddler* or teen* or
juvenile* or boy* or girl*)
S18 (MH “Adolescence+”)
S17 (MH “Child+”)
S16 (MH “Infant+”)
S15 S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14
S14 (acetaminophen or “acetylsalicylic acid” or “alendronic acid” or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or “choline magnesium trisalicylate” or clonazepam
or clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or
diazepam or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone
or “hyoscine hydrobromide” or ibuprofen or ketamine or ketoprofen or ketorolac or “levo bupivacaine” or lidocaine or loperamide
or lorazepam or mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous
oxide or nortriptyline or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or
“phenytoin” or piroxicam or pregabalin or propoxyphene or “risedronate sodium” or “sodium clodronate” or tetracaine or tramadol or
“valproic acid”)
S13 (MH “Steroids+”)
S12 (MH “Serotonin Uptake Inhibitors+”)
S11 (MH “Parasympatholytics+”)
S10 (MH “Muscle Relaxants, Central+”)
S9 (MH “Antiinflammatory Agents, Non-Steroidal+”)
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S8 (MH “Antidepressive Agents+”)
S7 (MH “Anticonvulsants+”)
S6 (MH “Anesthesia, Local”)
S5 (MH “Analgesics+”)
S4 S1 OR S2 OR S3
S3 (pain* or headache* or migraine* or neuralgia or neuropathic)
S2 (MH “Pain Management (Iowa NIC)”)
S1 (MH “Pain+”)
C O N T R I B U T I O N S O F A U T H O R S
Draft the protocol All
Develop a search strategy All
Search for studies (usually 2 review authors) EB, JL, HR, BC, LJ
Obtain copies of studies EB
Select which studies to include (2 + 1 arbiter) EB, BC, LJ
Extract data from studies (2 review authors) EB, VV
Enter data into RevMan EB
Carry out the analysis EB
Interpret the analysis All
Draft the final write-up of the review EB
Update the review EB, LJ, MB-L
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Serve as content expert RH, JL, RM
Take responsibility for grammar and language LJ
Serve as methodologist BC, VV
Serve as statistician VV
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The screening process changed from the protocol to the review. More studies emerged from the search strategy than anticipated and so
five review authors shared the screening, rather than two as stated in the protocol, with 10% of the abstracts being screened by a second
review author. Also, the data were extracted by one author and all were checked by a second author (rather than as per the protocol
with only the first few trials being extracted by two review authors and, when a consensus was reached, just one author continuing to
extract the rest). The type of intervention was widened to include not only a treatment that was intended primarily to treat pain but
treatments that acted as adjuvants, relieving pain as a secondary property. We were unable to report all secondary outcomes that were
not measuring pain or safety for all studies due to the large number of unrelated outcomes reported by some studies.
The title was amended from ’Pharmacological interventions for pain for life-limiting conditions in children and adolescents’.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Alendronate [adverse effects; therapeutic use]; Baclofen [administration&dosage]; BotulinumToxins, TypeA [administration&dosage;
adverse effects]; Cerebral Palsy [∗complications];Diphosphonates [adverse effects; therapeutic use];GastrointestinalDiseases [chemically
induced]; Injections, Spinal [adverse effects]; Neuromuscular Agents [administration&dosage; adverse effects]; Osteogenesis Imperfecta
[∗complications]; Pain [∗drug therapy; etiology]; Seizures [chemically induced]
MeSH check words
Adolescent; Child; Child, Preschool; Humans; Young Adult
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